sj-docx-1-tan-10.1177_17562864231221331 – Supplemental material for Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies

Butzkueven, Helmut; Kalincik, Tomas; Patti, Francesco; Slee, Mark; Weinstock-Guttman, Bianca; Buzzard, Katherine; Skibina, Olga; Alroughani, Raed; Prat, Alexandre; Girard, Marc; Horakova, Dana; Havrdova, Eva Kubala; Van der Walt, Anneke; Eichau, Sara; Hyde, Robert; Campbell, Nolan; Bodhinathan, Karthik; Spelman, Tim

doi:10.25384/SAGE.25298090.v1

sj-docx-1-tan-10.1177_17562864231221331.docx (56.57 kB)

sj-docx-1-tan-10.1177_17562864231221331 – Supplemental material for Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies

journal contribution

posted on 2024-02-27, 13:09 authored by Helmut Butzkueven, Tomas Kalincik, Francesco Patti, Mark Slee, Bianca Weinstock-Guttman, Katherine Buzzard, Olga Skibina, Raed Alroughani, Alexandre Prat, Marc Girard, Dana Horakova, Eva Kubala Havrdova, Anneke Van der Walt, Sara Eichau, Robert Hyde, Nolan Campbell, Karthik Bodhinathan, Tim Spelman

Supplemental material, sj-docx-1-tan-10.1177_17562864231221331 for Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies by Helmut Butzkueven, Tomas Kalincik, Francesco Patti, Mark Slee, Bianca Weinstock-Guttman, Katherine Buzzard, Olga Skibina, Raed Alroughani, Alexandre Prat, Marc Girard, Dana Horakova, Eva Kubala Havrdova, Anneke Van der Walt, Sara Eichau, Robert Hyde, Nolan Campbell, Karthik Bodhinathan and Tim Spelman in Therapeutic Advances in Neurological Disorders